pharmaphorum

NOVEMBER 19, 2020

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen are closing in after the FDA accepted a filing for their cut-price rival.

FDA Approval 63

FDA Approval Marketing Drugs Clinical Development 63

pharmaphorum

FEBRUARY 22, 2021

If a causal link is shown, it could have “significant ramifications” on the use of lentiviral vectors, a type of self-inactivating virus that underpins both approved cell therapies like Novartis’ CAR-T Kymriah as well as a host of experimental therapies that involve genetic manipulation of cells. million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

XTalks

DECEMBER 13, 2023

Related: Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod Casgevy and Lyfgenia Pricing and Warnings The price tags of both gene therapies are steep, given the complexity of developing gene therapies and as therapies meant to be one-time treatments. Vertex-CRISPR’s Casgevy has a US list price of $2.2

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

OCTOBER 26, 2021

The treatment came with an initial price tag of $39,000 per vial, which amounts to a total of $575,00 each year. Related: Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA. This is a huge development for patients.”.

Gene Silencing 98

Gene Silencing Gene Clinical Trials Clinical Trials 98

pharmaphorum

DECEMBER 23, 2022

Add to this the considerable cost of these medications – the first approved CAR-T, Novartis’ Kymriah (tisagenlecleucel), had a U.S. price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting.

Development 52

Development Drugs Clinical Development Antibody 52

XTalks

JUNE 8, 2021

Novartis’ Zolgensma (onasemnogene abeparvovec) gene therapy has been making significant strides as of late, including dosing of the first Spinal Muscular Atrophy (SMA) patient with the treatment in the UK last week. With a price tag of over $2.5 million, Zolgensma is currently the world’s most expensive drug.

Gene Therapy 110

Gene Therapy Gene Protein Trials 110

pharmaphorum

JUNE 2, 2021

The orally-administered drug is the third approved treatment for SMA after Biogen’s injectable Spinraza (nusinersen) and Novartis’ one-shot gene therapy Zolgensma (onasemnogene abeparvovec), which was administered to the first NHS patient this week. — Spinal Muscular Atrophy UK (@SMA_UK_) June 2, 2021.

Gene Therapy 52

Gene Therapy Gene Drugs Medicine 52

pharmaphorum

NOVEMBER 16, 2022

However, with a price tag of €1.58 The body has often gone against industry pricing models, notably in the case of Novartis’ Zolgensma (onasemnogene abeparvovec), which was previously the most expensive treatment in the world. How to navigate the new climate. At more than $2.1 At more than $2.1

Gene Therapy 131

Gene Therapy Gene Marketing Development 131

pharmaphorum

NOVEMBER 28, 2022

Substra is the software that powered the MELLODDY platform, a collaboration in which Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data — but not with each other directly, nor with Owkin.

Pharma Companies 71

Pharma Companies Life Science Research Development 71

XTalks

NOVEMBER 24, 2022

Prior to Hemgenix, bluebird bio’s recently approved gene therapy Skysona for the rare neurological disorder cerebral adrenoleukodystrophy (CALD) held the record for the highest-costing drug in the world at $3 million and before that, it was Novartis’ one-dose gene therapy Zolgensma which is priced at about $2 million.

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52

pharmaphorum

AUGUST 10, 2020

Evrysdi is the third treatment approved for SMA , an ultra-rare muscle wasting disease that can begin in early childhood, after Biogen’s Spinraza (nusinersen) and Novartis’ Zolgensma (onasemnogene abeparvovec). But Spinraza costs $750,000 in the first year of treatment and about half that price annually from then on.

FDA Approval 58

FDA Approval Drugs Gene Therapy Protein 58

XTalks

MARCH 22, 2023

The deal was surrounded by controversy as Swiss pharma Novartis was pushed out of the running by the French government, which reportedly sought to keep the companies’ combined economic power within the country’s borders. Within 2009 and 2010, Swiss pharmas Roche and Novartis acquired Genentech and Alcon , respectively.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Drug Discovery World

NOVEMBER 13, 2023

Stefan Ewert, PhD, Associate Director, Biologics Center, Novartis Institutes for Biomedical Research, on: ‘Computational counterselection identifies nonspecific therapeutic biologic candidates’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Characterisation of novel biotherapeutics This session will begin with chairperson’s remarks from Christian Graf, PhD, Fellow, Scientific Office, Novartis TRD Biologics. Thereafter, there will be three presentations before the plenary keynote session from Rebecca Croasdale-Wood, moderated by Enkelejda Miho.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

MAY 5, 2021

Ex-Novartis CEO Joe Jimenez and a lead Kite player take up new posts at an off-the-shelf rival ( Endpoints ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). Pfizer ups COVID-19 vaccine revenue estimates ( BioPharma Reporter ).

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52